Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 16630811 | HEPATITIS B VACCINE | April 2021 | July 2023 | Abandon | 42 | 2 | 0 | No | No |
| 17132182 | LIVE ATTENUATED ARKANSAS SEROTYPE INFECTIOUS BRONCHITIS VIRUS VACCINE | December 2020 | May 2022 | Allow | 16 | 2 | 0 | No | No |
| 17253467 | COMPOSITIONS AND METHODS FOR MAKING ENGINEERED T CELLS | December 2020 | March 2024 | Abandon | 39 | 1 | 0 | No | No |
| 16972897 | USE OF THE U94 MOLECULE OF HUMAN HERPESVIRUS 6 AND DERIVATIVES THEREOF TO INCREASE OR INDUCE THE EXPRESSION OF THE HLA-G MOLECULE | December 2020 | March 2024 | Abandon | 39 | 1 | 0 | No | No |
| 16972249 | HCMV VACCINE STRAIN | December 2020 | September 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 15734634 | VIRAL PARTICLE - BASED VACCINE | December 2020 | February 2024 | Allow | 38 | 4 | 0 | No | No |
| 17104024 | VARICELLA ZOSTER VIRUS VACCINE | November 2020 | April 2023 | Abandon | 29 | 2 | 0 | No | No |
| 17100573 | MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION | November 2020 | March 2023 | Allow | 28 | 3 | 0 | No | No |
| 17057378 | ANTIGEN VARIANT OF VARICELLA ZOSTER VIRUS AND USE THEREOF | November 2020 | February 2023 | Allow | 27 | 2 | 0 | No | No |
| 17095183 | METHOD OF PROVIDING SAFE ADMINISTRATION OF ADENOVIRAL VECTORS ENCODING A ZIKA VIRUS ANTIGEN | November 2020 | October 2023 | Abandon | 35 | 4 | 0 | No | No |
| 17086957 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY AND TREATING VIRAL INFECTIONS | November 2020 | February 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17087349 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS | November 2020 | May 2024 | Allow | 42 | 4 | 0 | Yes | No |
| 17051992 | HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE | October 2020 | January 2023 | Abandon | 26 | 2 | 0 | No | No |
| 17078877 | Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses | October 2020 | May 2023 | Abandon | 30 | 2 | 0 | No | No |
| 17060447 | CANCER TREATMENT AND DIAGNOSIS | October 2020 | June 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17060571 | ACTIVATION AND EXPANSION OF NKG2C+ NK CELLS | October 2020 | September 2022 | Abandon | 24 | 2 | 0 | No | No |
| 17061065 | ANTIGENIC RESPIRATORY SYNCYTIAL VIRUS POLYPEPTIDES | October 2020 | April 2024 | Allow | 43 | 1 | 0 | No | No |
| 17034934 | IMMUNOPOTENTIATOR, FOOT-AND-MOUTH DISEASE INACTIVATED VACCINE AND PREPARATION METHOD THEREOF | September 2020 | July 2022 | Allow | 21 | 1 | 0 | No | No |
| 17035109 | RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF | September 2020 | April 2022 | Allow | 18 | 1 | 0 | Yes | No |
| 17034706 | HBV VACCINES AND METHODS TREATING HBV | September 2020 | July 2022 | Allow | 21 | 1 | 1 | No | No |
| 17022475 | Method of Vaccination for SARS Virus | September 2020 | March 2022 | Abandon | 18 | 1 | 0 | No | No |
| 17020666 | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY | September 2020 | June 2022 | Allow | 21 | 2 | 0 | No | No |
| 17016993 | SCALABLE MANUFACTURING PLATFORM FOR VIRAL VECTOR PURIFICATION AND VIRAL VECTORS SO PURIFIED FOR USE IN GENE THERAPY | September 2020 | September 2023 | Allow | 36 | 3 | 0 | No | No |
| 17013156 | FLAVIVIRUS AND ALPHAVIRUS VIRUS-LIKE PARTICLES (VLPS) | September 2020 | March 2022 | Allow | 18 | 1 | 0 | No | No |
| 17013077 | CMV VECTORS AND USES THEREOF | September 2020 | December 2022 | Abandon | 27 | 2 | 0 | No | No |
| 17011488 | Use of Oncolytic Herpes Simplex Virus, Alone or in Combination with Immune Check-Point Inhibitor, in the Treatment of Cancer | September 2020 | January 2023 | Abandon | 28 | 2 | 0 | No | No |
| 16977679 | Protective Interfering Nucleic Acid Molecule and Virus-Like Particle, Viral Vector, or Virus Particle Containing the same as well as Pharmaceutical Composition Containing the Protective Interfering Nucleic Acid and its use | September 2020 | October 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 17009536 | MODIFIED AAV CAPSID PROTEINS AND USES THEREOF | September 2020 | August 2021 | Allow | 12 | 0 | 0 | Yes | No |
| 17006758 | Use of Triplex CMV Vaccine in CAR T Cell Therapy | August 2020 | January 2022 | Abandon | 16 | 1 | 0 | No | No |
| 16999158 | RECOMBINANT HERPES SIMPLEX VIRUS HAVING EXPRESSION CASSETTE EXPRESSING FUSED PROTEIN OF CANCER CELL-TARGETING DOMAIN AND EXTRACELLULAR DOMAIN OF HVEM AND USE THEREOF | August 2020 | July 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16971278 | SELF-ASSSEMBLING NANOSTRUCTURE VACCINES | August 2020 | April 2023 | Allow | 32 | 3 | 0 | Yes | No |
| 16995926 | RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS | August 2020 | December 2020 | Allow | 4 | 1 | 0 | No | No |
| 16995027 | ORAL VACCINES EXPRESSED IN YEAST FOR COVID-19 | August 2020 | November 2021 | Abandon | 15 | 1 | 1 | No | No |
| 16970084 | EPSTEIN-BARR VIRUS NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | August 2020 | March 2022 | Allow | 19 | 1 | 1 | Yes | No |
| 16967275 | RECOMBINANT HERPES SIMPLEX VIRUS-2 EXPRESSING GLYCOPROTEIN B AND D ANTIGENS | August 2020 | February 2022 | Allow | 19 | 2 | 0 | Yes | No |
| 16940304 | EPSTEIN-BARR VIRUS ANTIBODIES AND USES THEREOF | July 2020 | March 2022 | Allow | 20 | 2 | 1 | Yes | No |
| 16964348 | COMPOSITIONS AND METHODS FOR COMBINATION CANCER VACCINE AND IMMUNOLOGIC ADJUVANT THERAPY | July 2020 | December 2021 | Abandon | 17 | 3 | 0 | No | No |
| 16937109 | ORAL VACCINES EXPRESSED IN YEAST FOR COVID-19 | July 2020 | October 2021 | Abandon | 15 | 1 | 0 | No | No |
| 16964142 | NOVEL ADENO-ASSOCIATED VIRUS VIRION FOR TREATMENT OF TAY-SACHS DISEASE AND SANDHOFF DISEASE | July 2020 | April 2024 | Allow | 45 | 1 | 0 | No | No |
| 16934495 | CMV Glycoproteins and Recombinant Vectors | July 2020 | April 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16921239 | METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORS | July 2020 | August 2021 | Allow | 13 | 0 | 0 | Yes | No |
| 16916764 | EXOGENOUS GENE EXPRESSION IN RECOMBINANT ADENOVIRUS FOR MINIMAL IMPACT ON VIRAL KINETICS | June 2020 | March 2022 | Allow | 21 | 2 | 0 | No | No |
| 16912359 | DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS | June 2020 | January 2022 | Allow | 19 | 1 | 0 | No | No |
| 16897617 | METHODS FOR ANALYSIS OF VIRAL CAPSID PROTEIN COMPOSITION | June 2020 | January 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16896969 | Controlled Exposure to Pathogens for Generating Immunity | June 2020 | November 2022 | Abandon | 30 | 4 | 0 | Yes | No |
| 16770963 | EPSTEIN-BARR VIRUS ANTIGEN CONSTRUCTS | June 2020 | March 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 16896009 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS | June 2020 | February 2022 | Allow | 20 | 1 | 0 | No | No |
| 16760571 | STABLE FORMULATIONS OF CYTOMEGALOVIRUS | April 2020 | December 2022 | Abandon | 31 | 2 | 0 | No | No |
| 15929356 | CORONAVIRUSES EPITOPE-BASED VACCINES | April 2020 | April 2021 | Abandon | 12 | 1 | 0 | No | No |
| 16848397 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY AND TREATING VIRAL INFECTIONS | April 2020 | February 2023 | Abandon | 34 | 2 | 0 | No | No |
| 16842669 | CORONAVIRUS VACCINE | April 2020 | February 2021 | Allow | 10 | 2 | 0 | Yes | No |
| 16833409 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | March 2020 | May 2022 | Allow | 25 | 4 | 0 | Yes | No |
| 16650035 | PRODUCTION OF ADENO-ASSOCIATED VIRUSES IN INSECT CELLS | March 2020 | March 2023 | Abandon | 35 | 1 | 0 | No | No |
| 16828441 | VIRAL FORMULATIONS CONTAINING AMINO ACIDS | March 2020 | August 2021 | Abandon | 16 | 2 | 0 | Yes | No |
| 16826665 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | March 2020 | June 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16646894 | Human Cytomegalovirus Immunogenic Composition | March 2020 | July 2022 | Allow | 28 | 3 | 0 | No | No |
| 16646741 | Inducible AAV REP genes | March 2020 | March 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16812322 | Methods of Treating and Preventing Infections | March 2020 | August 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16812316 | Vaccine Compositions | March 2020 | June 2022 | Allow | 28 | 2 | 0 | Yes | No |
| 16799605 | FcRn-TARGETED THERAPEUTICS FOR THE TREATMENT OF ANTIBODY-MEDIATED AUTOIMMUNE AND ALBUMIN-MEDIATED DISEASE | February 2020 | May 2022 | Allow | 27 | 2 | 0 | Yes | No |
| 16641408 | ANTI-HSV GB MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | February 2020 | June 2022 | Allow | 28 | 2 | 0 | No | No |
| 16641432 | MODIFIED HSV GB PROTEIN AND HSV VACCINE INCLUDING SAME | February 2020 | April 2022 | Allow | 26 | 2 | 0 | Yes | No |
| 16641420 | MODIFIED HSV GD PROTEIN AND VACCINE CONTAINING SAME | February 2020 | February 2022 | Allow | 24 | 2 | 0 | No | No |
| 16640008 | MODIFIED MRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF | February 2020 | June 2021 | Allow | 15 | 1 | 0 | No | No |
| 16783597 | NOVEL TILAPIA VIRUS AND USES THEREOF | February 2020 | February 2021 | Allow | 13 | 1 | 0 | No | No |
| 16776403 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE TO VACCINATION | January 2020 | February 2022 | Allow | 24 | 2 | 0 | No | No |
| 16773938 | TREATMENT OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS | January 2020 | September 2021 | Allow | 20 | 1 | 0 | No | No |
| 16633875 | ANTIBODIES AND PEPTIDES TO TREAT HCMV RELATED DISEASES | January 2020 | July 2021 | Allow | 18 | 2 | 0 | Yes | No |
| 16633653 | ONCOLYTIC VIRAL VECTORS AND USES THEREOF | January 2020 | November 2022 | Allow | 33 | 1 | 0 | No | No |
| 16632853 | HERPES SIMPLEX VIRUS VACCINE EPITOPES SPECIFICALLY RECOGNIZED BY TISSUE RESIDENT MEMORY T CELLS | January 2020 | October 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16630972 | Composition for Treating and/or Preventing Hepatitis B Virus Infection and the Use Thereof | January 2020 | May 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16630624 | EXPRESSION SYSTEM FOR EXPRESSING HERPESVIRUS GLYCOPROTEIN COMPLEXES | January 2020 | March 2022 | Allow | 26 | 2 | 0 | Yes | No |
| 16738178 | Methods and Compositions Useful In Generating Non Canonical CD8+ T Cell Responses | January 2020 | April 2021 | Allow | 15 | 0 | 0 | No | No |
| 16718400 | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | December 2019 | April 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16707106 | MULTIVALENT RECOMBINANT AVIAN HERPES VIRUSES AND VACCINES FOR IMMUNIZING AVIAN SPECIES | December 2019 | May 2021 | Allow | 17 | 2 | 0 | No | No |
| 16620685 | BIVALENT VACCINE COMPOSITION FOR PREVENTING AND/OR TREATING PORCINE CIRCOVIRUS INFECTIONS AND PREPARATION METHOD AND USE THEREOF | December 2019 | June 2021 | Allow | 18 | 1 | 0 | No | No |
| 16618068 | ONCOLYTIC VIRUS AND METHOD | November 2019 | March 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16696403 | Cytomegalovirus Vectors Eliciting T Cells Restricted By Major Histocompatibility Complex E Molecules | November 2019 | December 2021 | Allow | 25 | 2 | 0 | No | No |
| 16616873 | RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE | November 2019 | November 2021 | Allow | 23 | 1 | 0 | No | No |
| 16613742 | IMMUNE ACTIVATION TRIGGERED BY FILOVIRUS PROTEINS AND POLYPEPTIDES | November 2019 | July 2022 | Abandon | 32 | 2 | 0 | No | No |
| 16680205 | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF | November 2019 | March 2022 | Allow | 28 | 2 | 0 | Yes | No |
| 16612265 | EPSTEIN BARR VIRUS ANTIBODIES, VACCINES, AND USES OF THE SAME | November 2019 | May 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16674710 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLUENZA | November 2019 | August 2022 | Abandon | 33 | 3 | 0 | No | No |
| 16665434 | 4/91 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN | October 2019 | October 2021 | Allow | 24 | 1 | 0 | No | No |
| 16609078 | EPSTEIN-BARR VIRUS ANTIBODIES AND USES THEREOF | October 2019 | January 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16608451 | HERPES SIMPLEX VIRUS VACCINE | October 2019 | February 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16664523 | COMPOUNDS THAT BIND TO HUMAN IMMUNODEFICIENCY VIRUS REV RESPONSE ELEMENT | October 2019 | February 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16608386 | ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION | October 2019 | September 2021 | Allow | 23 | 1 | 1 | Yes | No |
| 16663109 | Methods for Analysis of Viral Capsid Protein Composition | October 2019 | January 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16607412 | HSV ANTIGENIC PEPTIDES AND HSV PROTEIN VACCINES | October 2019 | June 2021 | Allow | 20 | 1 | 0 | No | No |
| 16606578 | CANCER VACCINES AND METHODS OF PRODUCING AND USING SAME | October 2019 | August 2021 | Abandon | 22 | 2 | 0 | No | No |
| 16657959 | METHODS OF ENHANCING BIOLOGICAL POTENCY OF BACULOVIRUS SYSTEM-PRODUCED RECOMBINANT ADENO-ASSOCIATED VIRUS | October 2019 | February 2023 | Allow | 40 | 1 | 0 | No | No |
| 16598982 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN | October 2019 | March 2020 | Allow | 5 | 3 | 0 | Yes | No |
| 16596239 | FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS | October 2019 | October 2023 | Allow | 48 | 5 | 0 | No | No |
| 16584356 | TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF | September 2019 | May 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16578178 | Oncolytic Herpes Simplex Virus and Therapeutic Uses Thereof | September 2019 | June 2021 | Allow | 21 | 1 | 0 | No | No |
| 16575784 | Compositions And Methods For Making And Using Virus-Like Particles (VLPs) | September 2019 | May 2021 | Allow | 20 | 1 | 0 | No | No |
| 16494988 | ZOONOTIC DISEASE RNA VACCINES | September 2019 | August 2021 | Abandon | 23 | 2 | 0 | Yes | No |
| 16573399 | TREATMENT OF CANCER BY INFUSION OF ONCOLYTIC HERPES SIMPLEX VIRUS TO THE BLOOD | September 2019 | March 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16571702 | Heat Stable Vaccines | September 2019 | July 2021 | Allow | 22 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GILL, RACHEL B.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GILL, RACHEL B works in Art Unit 1648 and has examined 647 patent applications in our dataset. With an allowance rate of 64.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner GILL, RACHEL B's allowance rate of 64.6% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by GILL, RACHEL B receive 2.06 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GILL, RACHEL B is 24 months. This places the examiner in the 80% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +32.0% benefit to allowance rate for applications examined by GILL, RACHEL B. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 43.4% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 92.3% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 91.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 85.4% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.3% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.